Небось, не вакцина, торопиться некуда

[borislvin]

В продолжение прошлогодней записи - вдруг появилась новость. Я-то, грешным делом, думал, что все заглохло на том, что Энливекс заработал что-то около 46 миллионов долларов на выпуске акций в феврале. Ан нет.

08/15/2021

Enlivex: After Review of Phase II Data, Israeli Ministry of Health Authorizes Initiation of a Multi-Center, Randomized Phase IIb Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today reported that after reviewing previously-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a proposed Company-sponsored, multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distressed syndrome (ARDS).

<...>

Nes Ziona, Israel, Aug. 15, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today reported that after reviewing previously-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a proposed Company-sponsored, multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distressed syndrome (ARDS).

The Phase IIb trial is expected to recruit up to 152 severe or critical COVID-19 patients in clinical centers in Israel and certain European countries, and is designed to assess the safety and efficacy of Allocetra when administered in addition to standard of care treatment.

Enlivex previously reported positive top-line results from Phase Ib and Phase II investigator-initiated clinical trials of Allocetra in COVID-19 patients in severe and critical condition. Aggregate data from the two trials demonstrated that AllocetraTM was safe and well tolerated. Moreover, at the end of the 28-day follow-up period, a 0% (0/21) mortality rate was observed and 90.5% (19/21) of patients recovered from their respective severe/critical condition and were discharged from the hospital after an average of 5.6 days following Allocetra administration.

https://www.globenewswire.com/news-release/2021/08/15/2280766/0/en/Enlivex-After-Review-of-Phase-II-Data-Israeli-Ministry-of-Health-Authorizes-Initiation-of-a-Multi-Center-Randomized-Phase-IIb-Clinical-Trial-Evaluating-Allocetra-in-Severe-and-Crit.html

https://enlivex.com/investor-relations/#latest-news

Все честь по чести - https://clinicaltrials.gov/ct2/show/NCT04922957

Comments

[(Anonymous)]

Сейчас непонятно, к сожалению или к счастью). Ощущение, что не только историю кое-где хотят переписывать, но и медицину. Про Израиль интересно, потому что они впереди по вакцинации, у них уже должны быть накоплены какие-нибудь данные по относительно отдаленным последствиям. Еще, конечно, хотелось бы понять характер и статистику осложнений по болезням.